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By targeting cells that provide protection against infection, HIV-1 causes acquired immun-
odeficiency syndrome. Infection starts when gp120, the viral envelope glycoprotein, binds
to CD4 and to a chemokine receptor usually CCR5 or CXCR4. As many microorganisms,
HIV-1 also interacts with heparan sulfate (HS), a complex group of cell surface associated
anionic polysaccharides. It has been thought that this binding, occurring at a step prior to
CD4 recognition, increases infectivity by pre-concentrating the virion particles at the cell
surface. Early work, dating from before the identification of CCR5 and CXCR4, showed
that a variety of HS mimetics bind to the gp120 V3 loop through electrostatic interactions,
compete with cell surface associated HS to bind the virus and consequently, neutralize
the infectivity of a number of T-cell line-adapted HIV-1 strains. However, progress made
to better understand HIV-1 attachment and entry, coupled with the recent identification of
additional gp120 regions mediating HS recognition, have considerably modified this view.
Firstly, theV3 loop from CXCR4-using viruses is much more positively charged compared to
those using CCR5. HS inhibition of cell attachment is thus restricted to CXCR4-using viruses
(such asT-cell line-adapted HIV-1). Secondly, studies aiming at characterizing the gp120/HS
complex revealed that HS binding was far more complex than previously thought: in addi-
tion to the V3 loop of CXCR4 tropic gp120, HS interacts with several other cryptic areas of
the protein, which can be induced upon CD4 binding, and are conserved amongst CCR5
and CXCR4 viruses. In view of these data, this review will detail the present knowledge on
HS binding to HIV-1, with regards to attachment and entry processes. It will discuss the
perspective of targeting the gp120 co-receptor binding site with HS mimetic compounds,
a strategy that recently gave rise to entry inhibitors that work in the low nanomolar range,
independently of co-receptor usage.
Keywords: heparan sulfate, glycosaminoglycan, CCR5/CXCR4, gp120, V3 loop, co-receptor binding site, HIV-1,
attachment and entry inhibition
INTRODUCTION
HIV-1 is the causative agent of acquired immunodeficiency syn-
drome (AIDS), a condition in humans in which progressive fail-
ure of the immune system leads to the development of severe
opportunistic infections and unusual malignant disorders (1).
Infection occurs through the transfer of blood, semen, vaginal
fluid, or breast milk, in which HIV-1 can be present as both free
virus particles and/or within infected cells. The virus infects vital
cells of the immune system, including CD4+ T-helper lympho-
cytes, macrophages, and dendritic cells, all of which are key to
the development and orchestration of the immune response (2).
This results in the targeted depletion of CD4+ T cells, the main
function of which is to promote cytotoxic T-lymphocyte depen-
dant killing of cells expressing foreign antigens and up regulate
antibody production by B-lymphocytes. When CD4+ T cells num-
bers decline below a critical level (400/µl of blood) cell-mediated
immunity is compromised and the body becomes progressively
more susceptible to opportunistic infections (3). The first step
of the HIV-1 replication cycle, attachment and entry into host
cells, occurs through specific interactions between gp120, the gly-
coprotein which constitutes the surface unit of HIV-1 envelope
spikes (Env) and the primary cellular receptor,CD4. This promotes
further contacts between gp120 and members of the chemokine
receptor family, among which CCR5 and CXCR4 are the most
physiologically relevant and ultimately lead to the fusion of the
viral and the host cell membranes (4). HIV-1 preferentially uses
CCR5 during the acute phase of infection but, later in the course
of HIV-1 infection progressing to AIDS, HIV-1 variants frequently
appear that become adapted to utilize CXCR4.
Before encountering permissive CD4+ cells the virus may
interact with several other alternative receptors, often referred
as “attachment receptors” (5) such as Galactoside Ceramide
(GalCer), present at the surface of epithelial cells, Mannose-
Binding Lectin (MBL), Dendritic Cell Specific ICAM-3-Grabbing
Non-integrin (DC-SIGN), or Heparan Sulfate Proteoglycans
(HSPGs), the latter being present at the surface of virtually all
cell types. Although these interactions generally do not per-
mit infection per se, they can importantly affect mucosal cells
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(the portal through which HIV-1 enters in the body) attach-
ment and transport across epithelial layers, tropism, tissue inva-
sion, or cellular entry (6, 7). This review will discuss some
aspects of the HIV-1-HSPG interaction and will describe how
the biochemical characterization of this interaction led to the
engineering of a new class of potential attachment and entry
inhibitors.
HEPARAN SULFATE PROTEOGLYCANS
Heparan sulfate proteoglycans are glycoproteins carrying one or
more covalently bound heparan sulfate (HS) chains, a large anionic
polysaccharide of the glycosaminoglycan (GAG) family, character-
ized by astonishing structural diversity and interactive properties.
These complex molecules are widely distributed within tissues,
and can be found at the cell surface such as the syndecans and
glypicans, within the extracellular matrix such as agrin, perlecan,
or type XVIII collagen, or intracellularly such as serglycin (8).
Being predominantly and ubiquitously present in the extracellular
milieu, these macromolecules are unsurprisingly playing essential
roles in a vast number of biological processes occurring at the
cell–cell and cell–matrix interface.
Over the past two decades, HSPGs have been found indeed
to bind to a multitude of protein ligands, including cytokines,
chemokines, morphogens, growth factors, adhesion and matrix
molecules, receptors, enzymes, plasma proteins, etc. (8, 9). These
interactions, which usually involve the HS chains, serve a large
number of purposes. Functionally,HS has been known to affect the
local concentration, the compartmentalization, the stability, the
structure,and/or the activity of its ligands. Protein-HS interactions
thus play critical roles, for example, in mediating the formation of
chemokine gradients along which cells can migrate directionally
(10–12), in providing a scaffold onto which two adjacent pro-
teins such as growth factor-receptor complexes can interact (13),
in protecting cytokines against proteolysis (14), in inducing pro-
tein conformational changes (15), in controlling or in restricting
the diffusion of its ligands (16–18) thereby generating a local con-
centration of a given protein. As it will be described below, many
microbial pathogens hijack HSPGs and take advantage of their
interactive properties for their adhesion to host tissues and inva-
sion of host cells. From a structural view point HSPGs’ multiple
binding activities are believed to be closely related to the extended
structural variability of the HS chain. It is a long (20–150 nm) and
linear polysaccharide made of a repeating units of a 1→ 4 linked
disaccharide motifs, comprising a glucuronic acid (GlcA) or its C-5
epimer, an iduronic acid (IdoA), and a N -acetyl- or N -sulfated-
glucosamine (GlcNac or GlcNS), either or both of which may be
O-sulfated at different positions. Variation in length, sulfation, and
glucuronate/iduronate ratio, which occur in restricted domains
of usually three to six disaccharides along the chain (Figure 1),
generates a very large polydispersity and, as such, provides dis-
tinct docking sites for the various ligands of the polysaccharide
(19, 20).
FIGURE 1 | Heparan sulfate structure. HS, whose biosynthesis is initiated
by the attachment of xylose (star) to specific serine residues in HSPG core
proteins, followed by the formation of a linking tetrasaccharide
(xylose-galactose-galactose-glucuronic acid), is initially polymerized by an
enzyme complex composed of Ext1 and Ext2 as a GlcA-GlcNAc repeat (black).
In restricted regions, called S-domains (shown in red), the chain is extensively
modified by a series of enzymatic reactions that remove the acetyl group
from GlcNAc residues and substitute the resulting free amino groups with
sulfates, epimerizes the adjacent GlcA into L-iduronic acid (IdoA) and adds
sulfates on various positions: the C2 of the IdoA (and less frequently that of
the GlcA), the C6 of the GlcNS (and less frequently that of the GlcNac), and
finally at the C3 of GlcNS or GlcN units. Altogether, these modifications can
generate (the theoretical number of) 48 different disaccharides, whose
combination within the S-domain gives rise to a large diversity of structures
and make up binding sites for protein ligands, as depicted for example with a
model of a CXCL12-HS complex [from Ref. (21)].
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HSPG AND PATHOGENS
Attachment to host tissues is a critical step for most pathogens’
invasion and dissemination. It is therefore not very remarkable
that due to its wide expression and large interactive properties,
HS is used by many pathogens for that purpose (22–26). These
include parasites, for example Plasmodium falciparum (27) bacte-
ria, such as Pseudomonas aeruginosa (28), Borrelia burdorferi (29),
or Mycobacterium tuberculosis (30), and many viruses, amongst
which are found B (31), C (32), delta (33), and E (34) hepatitis
viruses, Human Papillomavirus (35), Herpes viruses (36), HTLV-1
(37), or HIV-1 (38). Several lines of evidence have identified HS as
an initial receptor for viral infection. Firstly, many capsid or enve-
lope viral proteins bind to HS, secondly, elimination of cell surface
HS is usually associated with increased cell resistance to infection
that results from a reduction in the virus’ ability to bind to the
cell surface (39), thirdly, soluble HS or HS like molecules, includ-
ing heparin, a chemically related GAG and dextran sulfate, inhibit
viral attachment and subsequent entry in cell culture experiments
(40–42). Finally, it has been described that a number of viruses
undergo cell culture adaptation changes resulting in an increased
binding to HS (43–46). Together this suggests that selection dur-
ing cell culture of mutants that bind HS with high affinity confer
a selective advantage to the viruses. It has thus been thought that
HS could facilitate concentration of the viral particles at the cell
surface, restricting their diffusion to the quasi-two-dimensional
network of polysaccharides around the cell and as such enhances
the probability of access to specific entry receptors. HS can also
capture viral particles at the surface of non-permissive cells, and
then mediate in trans infection by presenting these viruses to
attachment and entry receptors on permissive cells (47). HS bind-
ing can also go well beyond the simple attachment mechanism and
can play a more direct role in cellular entry. This has been demon-
strated in particular for HSV, a virus whose entry into epithelial
cells involves several glycoproteins of the envelope (48). While the
viral envelope glycoproteins gB and gC participate in the initial
cell attachment through binding to HS, the gD, which binds to
herpes virus entry mediator (HVEM) or to nectin, triggers fusion
between host and viral membranes, but can also promote viral
entry by interacting with a specific HS motif comprising a 3-O-
sulfated glucosamine residue (49). Interestingly, a 3-O-sulfonated
HS octasaccharide, produced by chemical means, was shown to
inhibit the HSV-1 host-cell interaction (50), suggesting the use of
HS derived molecules as therapeutic tools against viral pathogens.
WHERE DOES HIV-1 MEET HS?
HIV-1 is transmitted by viral exposure at the mucosal surfaces,
which can occur in the genital tract (semen, blood) the intesti-
nal tract (semen, blood, breast milk), or through the placenta
(maternal blood), or the bloodstream (blood products). Within
the context of vaginal or rectal transmission, HIV-1 must first cross
a normally protective mucosal epithelium to reach the underlying
dendritic cells, macrophages, and T cells which all express the virus
primary receptor, CD4 and at least one of its two co-receptors,
CCR5 or CXCR4, and are thus the three major cellular targets
of HIV-1. In these early events of transmission, before specific
cell infection, HS has been shown to play important roles in viral
adsorption and dissemination. In the semen first,which is the main
vector for HIV-1 dissemination, and which contains both free viri-
ons and infected leukocytes, it has been found that spermatozoa
can capture HIV-1 in a HS dependant manner. Such spermatozoa-
attached viruses are efficiently transmitted to dendritic cells,
macrophages, and T cells (51) to which access could be made pos-
sible through mucosal microabrasions or through dendritic cell
projections that extend to the luminal surface of the mucosa.
The mechanisms used by free or cell associated virions to cross
an otherwise healthy mucosal barrier are not well known and
might differ depending on the tissue sites (for example vaginal or
rectal epithelium) where infection occurs (52). HIV-1 can interact
with the epithelial cells and can traverse the epithelium through
transcytosis, endocytosis followed by exocytosis or by penetrating
the gaps in between cells, gaining access to susceptible leukocytes
that will further propagate and spread the infection (53, 54). In this
context, it has been well known that epithelial cells express large
amount of HSPGs which can sequester HIV particles. For example,
attachment of HIV to an ectocervical epithelium-derived cell line
can be inhibited both by heparinase (an enzyme that depolymer-
izes HS and removes it from the cell surface) or by soluble heparin.
Interestingly, it has been found that cell surface bound HIV parti-
cles remain infectious for at least 6 days, and upon co-culture with
CD4+ cells, can be efficiently transmitted to its target cells (55).
It has been also reported that HSPG significantly contributes to
both attachment to the apical pole of – and transcytosis through –
an endometrial epithelium-derived cell line (7). Similarly, cell-free
HIV particles have been shown to transcytose (although with low
efficiency) through primary genital epithelial cells, a process that
was dependant on syndecan, one of the major HSPGs expressed
by epithelial cells (56).
Finally, HS was recently found to be indispensable for gp120-
mediated induction of TLR signaling in intestinal and genital
epithelial cells. In the gp120-TLR-HS complex, HS was critical
to activate the intracellular NF-kB pathway which lead to down-
stream synthesis of proinflammatory cytokines and chemokines,
and whose upregulation was associated with tight junction disrup-
tion and loss of barrier function (57). Therefore, beyond acting as
an ancillary attachment receptor, HS can contribute to barrier
loss and initiation of immune activation that could be the first
step in the characteristic chronic immune activation of HIV-1
pathogenesis.
Primary infection can also develop from viral exposure in the
oral cavity (mother to infant nursing or during oral intercourse),
where the palatine tonsil is a replication site for HIV-1. Studies
aiming at characterizing the expression pattern for HIV-1 ligands
on human palatine tonsils have shown that HS was largely present
on both the surface of the stratified squamous epithelium and on
the reticulated epithelium lining the tonsillar crypts and where it
is likely to provide stable binding for the virus, allowing it to pene-
trate beneath the luminal surface and encounter CD4+ cells (58).
Finally, it has also been shown that HIV-1 infection of trophoblasts
is independent of CD4 but, at least partly, relies on HSPG. Mother
to child vertical transmission of the virus is a major cause of HIV-1
infection in infants, and direct infection of trophoblasts, the cells
that form the placental barrier, may cause this transmission (59).
HIV-1 is also trapped very efficiently by endothelial cells, which
usually express large amounts of HSPG. Syndecan-3, for example,
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which delineates the contour of endothelial cells in lymphoid tis-
sue high endothelial venules, does not substitute for HIV-1 entry
receptors but captures HIV-1 and presents it to passing permis-
sive T cells, thus mediating an in trans mechanism of infection.
Furthermore, whereas unbound viruses lose infectivity in 1 day,
syndecan-attached HIV-1 remains infectious for up to 1 week (60).
Finally, HSPGs also significantly contributes to HIV-1 invasion
in the brain and neurological complications that often character-
ize AIDS patients. Whereas HIV-1 can enter the central nervous
system within infected CD4+T-cell and monocytes that traffic
across the blood brain barrier, several in vitro and in vivo reports
described that free HIV-1 can be taken up by brain endothelial
cells in a HS dependant manner, internalized and exocytosed, as
a way to cross the blood brain barrier before infection and repli-
cation can occur in central nervous system cells such as microglia
and astrocytes (61–63).
Although this review is devoted to HIV-1 attachment and
entry, it is worth noting that, in addition to gp120, several other
HIV proteins regulating various aspects of the virus life cycle
also appeared to bind cellular HS after being released from HIV-
infected cells. These protein-HS interactions contribute to trigger
a variety of biological effects related to AIDS-associated patholo-
gies. This includes p17, the matrix protein (64) which up-regulates
cytokine production thus deregulating the functions of many
immune cells; TAT, the transacting activator of transcription (65)
which exerts angiogenic, cell proliferation, chemoinvasion activ-
ities and induces peripheral neuropathies, immune suppression,
and tumorigenesis; and finally Vpr, the Viral protein R (66), which
induces cell cycle arrest and apoptosis.
Altogether, regarding attachment and entry, these studies
showed that HSPG serves a number of purposes during the early
steps of HIV-1 dissemination, from capturing and presenting in
trans free virions to replicative cells, to permitting the transfer of
viral particles across epithelial or endothelial barriers (Figure 2).
HSPG, when expressed by CD4+ permissive cells may also increase
infectivity by favoring in cis viral particle concentration at the cell
surface (see below).
A number of polyanions have been investigated for their ability
to inhibit HIV-1 infection in clinical trials. In addition to suramin,
dextran sulfate, and heparin, which were considered for systemic
use, this includes many other sulfated/acidic compounds such as
carrageenan, cellulose sulfate, polystyrene sulfonate or maleic acid,
naphthalene sulfonate, and cellulose acetate phthalate, developed
as anti HIV-1 microbicides. Unfortunately, none of these com-
pounds proved to be effective in vivo presumably due to poor
availability, toxicity, sequestration by plasma proteins, induced
reduction in epithelial integrity and concomitant increases in per-
meability to HIV-1 particles (67, 68). Their variability, in terms
of molecular weights and degrees of sulfation also made them
difficult to standardize.
THE CELL SURFACE LIGANDS OF gp120 AND THE ENTRY
PROCESS
CD4, CCR5, AND CXCR4
Once in contact with permissive cells, i.e., cells that are CD4 and
CCR5 and/or CXCR4 positive, the HIV-1 can start its replica-
tion cycle. HIV-1 entry into its target cells is initiated by a highly
complex series of interactions, which first involve the binding of
gp120 to its primary receptor, CD4 (69). This initial step not
only enables the viral particles to attach to the cell, but also dri-
ves extensive structural alterations that primes the envelope for
binding to either CCR5 or CXCR4 (70). This second interaction,
which elicits further modifications in Env, triggers the activation
of the gp41 fusion peptide whose insertion into the host mem-
brane ultimately leads to the delivery of the viral contents into
the host cytoplasm (Figure 3). The gp120 thus constitutes the
central element for all interactive events occurring during the
pre-entry steps and, accordingly, this molecule features several
interactive regions and is structurally complex; It consists of five
relatively conserved regions (C1–C5), that fold into a “core” struc-
ture organized into two distinct regions termed the “inner” and
“outer” domains that are connected by a bridging segment, and
five surface-exposed variable loops (V1–V5). The CD4 binding
site is formed from conserved residues in discontinuous segments
FIGURE 2 | In cis and in trans capture of HIV-1 by heparan sulfate. HS can
play multiple roles during viral infection. (A) On top of cells that express large
amount of HS, but low CD4, such as macrophages, HS can capture viral
particles and facilitate in cis subsequent interaction with specific entry
receptors. (B) HS from non-permissive cells such as endothelia or epithelia
can sequester HIV-1 and then mediate in trans infection by presenting the
virus to permissive cells. (C) HS can contribute to both attachment and
transcytosis of HIV-1 through epithelia.
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FIGURE 3 | HIV-1 entry mechanism. (A) Schematic representation of the
multi-step process of HIV-1 entry; from attachment to CD4 (left) to fusion
between the viral and the cell membrane (right). The gp120 trimer, upon
binding to CD4 (in green), experiences extensive structural changes that open
up the variable loops V1/V2 and V3 (orange and yellow), and concomitantly
expose and/or fold the so called CD4 induced bridging sheet that will be
recognized by the co-receptor (CCR5 and/or CXCR4). This second interaction
triggers the insertion of the gp41 fusion peptide into the cell membrane and
promotes viral entry (Reprinted from Ref. (102), with permission from
Elsevier). (B)Three-dimensional structure of gp120 in the CD4-bound
conformation (from pdb:2b4c), showing the inner and outer domains, the
V1/V2 loop stem, and the four β strands (CD4 induced bridging sheet in blue)
that together with the V3 loop (in green) contribute to co-receptor selectivity
and interaction.
of the C1, C3, and C4 domains that are brought into proxim-
ity in the folded gp120 and located into a depression formed at
the interface of the outer and inner domain and the region that
connects these two domains (71). Binding to CD4 triggers exten-
sive structural alterations, in particular within the inner domain
of the protein. Although X-ray crystallographic analysis have led
to atomic models for gp120 on which the V1/V2 and V3 loops
were deleted, it seems likely that these structural modifications
include both a relocation of the V3 and shifts of the V1/V2 loops,
whose base in the inner domain (β2 and β3 strands) is brought
into close proximity to a β-hairpin of the outer domain (β20 and
β21 strands). This exposes new regions that, partially masked by
the V1/V2 and V3 loops, were cryptic in the unliganded gp120,
and concomitantly folds a four-stranded β-sheet located within
the bridging sheet that connects the inner and the outer domain
of the glycoprotein (71, 72). In conjunction with the V3 loop (73),
this β-sheet (known as CD4i for CD4 induced epitope) makes
up the binding site for either CCR5 or CXCR4 (70, 74, 75). The
V3 loop has a major influence on HIV-1 tropism and appears to
be a key determinant for co-receptor selectivity, which in turn,
affects the overall process of viral pathogenesis. Its sequence is
important for defining the extent to which the CD4-bound form
of the gp120 interacts with CCR5 or CXCR4, and hence the abil-
ity of a particular HIV-1 virus to enter cells using either CCR5
(viruses called R5-tropic) or CXCR4 (X4-tropic viruses). R5X4 or
dual tropic strains constitute a third class that can use either of
these two co-receptors. It has been reported that in the major-
ity of the infected subjects, the HIV-1 primarily uses CCR5 in
order to initiate the infection. However, during the course of
infection, the co-receptor usage preference of HIV-1 shifts from
CCR5 to CXCR4 in 50% of the infected individuals, a change
that is frequently associated with the accelerated CD4+ T-cell
decline and the rapid progression toward AIDS. In the context of
the interaction between gp120 and HS, it is worth noting that,
in general, the R5 to X4 tropism switch is associated with an
increase in the net positive charge of the V3 loop (75), which
will also determine to which extent gp120 will interact with HS
(see below).
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HEPARAN SULFATE
Very early in the study of HIV-1, it was found that a number of
HS like molecules, including heparin, dextran sulfate, and various
heparinoids (such as pentosan polysulfate, fucoidan, curdlan sul-
fate) inhibit viral replication in cell culture experiments (76–78).
This appeared to mostly occur by preventing HIV-1 binding to
the cell surface as shown by the ability of heparinase treatment
of HIV-1 sensitive lymphoblastic T-cell lines, such as MT-4 and
H9, to reduce HIV-1 absorption to these cells (38, 79). Although
some studies suggested that heparinoids could bind to CD4 and
thus interfere with HIV-1 binding to its primary receptor, several
investigations showed that both soluble heparin and cell surface
HS interact with gp120 (see below) and target the V3 loop of the
viral protein (80, 81). As this domain is not involved in CD4 bind-
ing, this excluded that heparinoid works by blocking the gp120-
CD4 interaction, which was further confirmed by the observation
that (i) HS could be immunoprecipitated from gp120 treated H9
cells with either anti gp120 or anti-CD4 antibodies (82), and (ii)
dextran did not interfere with the binding of CD4 to recom-
binant gp120 at concentrations which effectively prevent HIV-1
replication (83, 84). Interestingly, it was shown that if the polyan-
ionic nature of these compounds were essential for their in vitro
anti-HIV-1 activities, a number of other sulfated polysaccharides,
including for example various chondroitin sulfates (another mem-
ber of the GAG family), have no such activities. This suggests that
specific structural features of the polysaccharide might be impor-
tant for activity. It thus appears that, in addition to CD4, cell
surface HSPG functions as an attachment receptor recognized by
the V3 loop of gp120, and therefore suggesting that this interaction
allows the virus to scan the cell surface and could assist binding to
specific entry receptors. Most of these studies however date back
to the discovery of the HIV-1 co-receptors and their importance
in tropism. They were performed with T-cell line-adapted HIV-1
that use CXCR4 to enter cells and immortalized T-cell lines that
express large amounts of HSPG. The binding of HIV-1 to cell sur-
face HSPG is however likely to depend on the level of expression
of this molecule, and it was then reported that if cell surface HSPG
facilitates HIV-1 entry into some cell lines it does not into primary
T-lymphocytes (85, 86), questioning the physiological relevance
of HSPG for capturing viral particles at the surface of CD4+ cells.
Primary T-lymphocytes and macrophages, the two major HIV-
1 targets, feature opposite patterns of attachment receptors. In the
former, which express high CD4 levels, chondroitin sulfate largely
outnumbers HS moieties (87), while macrophages display low lev-
els of CD4 but produce large amount of HS (88). On these cells,
HIV-1 attachment is mostly mediated by HSPGs, and this inter-
action was found necessary for successful infection when a low
level of CD4 is expressed at the cell surface (88, 89). Thus, HS
may compensate for low level CD4 expression and induce a suf-
ficiently high viral particle concentration for infection that CD4
by itself would not achieve. In contrast, the high levels of CD4
on T-lymphocytes obviate the need for other attachment mole-
cules. Together, this shows that the role of HS in mediating in cis
HIV-1 infection may depend on the cell surface CD4/HS ratio and
their level of regulation. For example, it has been observed that
while quiescent primary CD4+ T cells do not express detectable
levels of HSPGs, HSPGs are expressed on primary CD4+ T cells
following activation by interleukin-2/phytohemagglutinin or anti-
CD3/anti-CD28 antibody. This immune activation coincides with
binding and entry of HTLV-1, a known HS binding virus (90).
Although determining the GAG nature/expression pattern and
architecture of primary cells is not trivial, it might be of inter-
est to better characterize the HS status of HIV-1 target cells during
the evolution of the pathogenesis. Finally, it is also important to
note that HIV-1 susceptibility to HS is dependant on the HIV-1
strain as all do not display high affinity for this GAG (see below).
A BIOCHEMICAL VIEW ON THE gp120-HS INTERACTION
THE V3 LOOP IS THE MAJOR HS BINDING DETERMINANT
Early studies, investigating the mechanism by which polyan-
ions such as heparin or dextran sulfate inhibit HIV-1 replication
pointed out that these polysaccharides interact with the gp120 V3
loop. This was essentially based on the observation that polyanions
block the binding of a number of monoclonal antibodies, directed
against the V3 loop to either recombinant gp120 on ELISA plates
or to HIV-1 infected cells expressing gp120 on their surface (80, 82,
84). These results were further confirmed with data showing that
HS directly binds to V3 derived peptides (81, 91), whose sequences
were characterized by Lys and Arg enriched clusters that are com-
monly found on protein HS binding sites. However, the V3 loop,
a disulfide-bonded structure of approximately 35-residues-long is
highly variable and prone to mutation-induced sequence changes
(75). Its overall charge may vary from +2 to +10, with that of a
CCR5-using HIV-1 strain generally in the range of +3 to +5 and
that of a CXCR4-using isolate being from +7 to +10. Therefore,
binding to HS may vary according to the gp120 origin and tro-
pism, an evolution toward a more basic structure being linked to
adaptation toward CXCR4 usage.
To investigate these points in more detail, the binding of heparin
to WT and mutated forms of different gp120s, including MN (X4),
HXBc2 (X4), 89.6 (R5X4), W61D (R5X4), Bal (R5), and JRFL (R5)
were measured by different means: Surface Plasmon Resonance
showed first that the X4-HXBc2 gp120 (whose V3 loop features
nine positive charges) strongly binds to heparin, as does the R5X4-
89.6 gp120 which has seven positive charges in its V3 loop. The
binding of the W61D (another R5X4 gp120 with a V3 loop of+6)
was reduced, and finally, the R5-gp120 (whose V3 loop contains
only four basic residues) binds relatively weakly (gp120 Bal) or not
at all (gp120 JRFL). These results were in agreement with another
assay, in which the interaction of [35S]-labeled heparin to the above
mentioned gp120s also showed that most of the variation in bind-
ing is due to changes in the charge and structure of the V3 loop.
It was nevertheless observed that [35S]-labeled heparin binding to
HXBc2 gp120 was not entirely suppressed by the V3 loop dele-
tion, suggesting that other regions could contribute, albeit to a
lesser extent. Binding of HXBc2 with more substantial deletions,
performed to address which other regions of the X4-gp120 might
be implicated, showed that deletion of the NH2- and COOH-
termini and the V1/V2 loop structure resulted in a small loss of
[35S]-heparin binding. An additional deletion of the V3 loop dra-
matically reduced [35S]-heparin binding and preincubation of this
mutant with the monoclonal antibody 48d further reduced bind-
ing to background levels. These data suggest that whereas the V3
loop is the major determinant, the COOH- and NH2-termini, the
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V1/V2 loops and the bridging sheet between the inner and outer
domains of gp120 (recognized by the 48d antibody) could con-
tribute to some extent to the binding of polyanions. Consistently
with the idea that the V3 loop is the primary high affinity binding
site on gp120, at least for the X4 derived Env, molecular model-
ing of the electrostatic potential of the protein confirmed that the
overall charge on the surface is dominated by the V3 loop (92).
The early use of polyanionic compounds such as dextran sul-
fate as anti- HIV-1 therapeutic agents has not been successful in
clinical trials (93). One possible reason for the in vivo failure of the
molecule (in addition to toxicity and poor bioavailability) could
be related to the V3 loop charge differences between R5 and X4
viruses, the former being the phenotype associated with HIV-1
transmission and early infection, while the latter being the only
one efficiently targeted by polyanions.
HS BINDING TO OTHER SURFACE EXPOSED REGIONS OF gp120
To obtain unequivocal evidence for a direct interaction between
polyanions and regions outside the V3 loops, a new approach
designed to identify and simultaneously map potential HS bind-
ing sites on a protein surface was developed (94). This method,
which uses unmodified native proteins, is based on the forma-
tion of cross-linked complexes of the protein of interest with
heparin, followed by the proteolytic digestion of these complexes,
and the subsequent identification of the heparin bound peptides
by N-terminal sequencing using an automated protocol of Edman
degradation and HPLC detection of the released amino acids.
Using this approach with HXBc2 gp120, three potential HS
binding domains (HBDs) were consistently identified (including
the V3 loop that was confirmed by this approach): RGKVQK
(HBD 1: residues 166–171) located within the V2 loop, RKRIR
(HBD 2: residues 304–308) at the base of the V3 loop and finally,
KAKRR (HBD 3: residues 500–504), at the C-terminal domain of
the protein (95).
Interestingly, all three HBDs are functionally important. HBD
1 and 2 in particular undergo important structural changes after
CD4 binding, resulting in the unmasking of the co-receptor bind-
ing site and are thus key to the entry mechanism of the virus.
As mentioned above, HBD 2 (within the V3 loop, which deter-
mines co-receptor usage) displays essential features for co-receptor
binding. In particular, mutation of residues Arg298, Arg306, and
Arg308, present in this HBD, strongly decrease the ability of gp120
to interact with CXCR4 (96). It has been reported that heparin
enhances the furin cleavage of HIV-1 gp160 into gp120 and gp41,
which occurs only three residues downstream HBD 3, but the
significance of this observation is not clear (see Ref. (95) for
discussion).
Together these data provide a direct demonstration of the exis-
tence of additional binding sites and identify some of the residues
involved. They are consistent with a kinetic analysis of the gp120-
heparin interaction which could be much better described by a
complex model than by a single one-to-one binding mode (92) and
with the observation that the V3 loop does not fully recapitulate
the binding activity of the protein.
A FOURTH HS BINDING SITE IN gp120: THE “CD4 INDUCED” EPITOPE
The gp120 molecules assume several distinct conformations and
are characterized by an important intrinsic flexibility, which could
likely influence heparin binding. As described above, and as shown
by cryo-electron tomography on the native gp120 trimers (includ-
ing the variable loops that were missing in the X-ray crystallo-
graphic analysis), the V1/V2 and V3 loops (comprising the HBD 1
and 2), in particular, are released and move away from the center
of the Env spike (97) following binding to CD4. Thus, to fur-
ther clarify the gp120-HS binding determinant, the unliganded
monomeric gp120 (HXBc2 strain) and the gp120 in its CD4-
bound conformation, were compared for their ability to interact
with heparin. This showed that in its CD4-bound form, gp120
had a substantially increased affinity for the polyanion, suggest-
ing that the CD4-bound conformation could have improved the
accessibility of the V1/V2 and V3 loops and/or stabilize them into
a structure better recognized by HS.
However, CD4 binding also exposed the “CD4 induced” bridg-
ing sheet that was previously masked by the V1/V2 and V3 loops in
the unliganded form. Examination of the gp120 electrostatic sur-
face, using the structural data of the CD4-bound core glycoprotein,
revealed that the CD4 induced region comprises a cluster of posi-
tively charged residues located between the stems of the V1/V2 and
V3 loops, organized as a typical HS binding site (Figure 4). Using a
molecular modeling approach to locate putative HS binding sites
further shows that within this domain, amino acids Lys-121, Arg-
419, Lys-421, and Lys-432 form a discontinuous surface with a
linear shape extending up to 25 Å, which can be predicted by a
GRID analysis to be the most favorable anchoring position for an
oxygen atom from a sulfate group (98). These molecular model-
ing predictions could be confirmed by showing that HS and HS
derived oligosaccharides strongly inhibited the binding of mAb
17b to the CD4-gp120 complex. The mAb 17b belongs to the
CD4i antibody family and recognizes an epitope on the gp120
bridging sheet that is exposed upon CD4 binding. Interestingly,
this sterically restricted region, which overlaps the binding site for
the co-receptor, is a well conserved element amongst X4, R5, and
dual tropic gp120. Mutagenesis then confirmed that of the four
amino acids indicated above, Arg-419, Lys-421, and Lys-432 were
key to the interaction with HS (95). All together, this defines an
additional HS binding domain (HBD 4), located within the gp120
bridging sheet, importantly involved in co-receptor recognition
and exposed only after CD4 binding.
DEVELOPMENT OF A CD4-HS GLYCOCONJUGATE TO INHIBIT
HIV-1 ATTACHMENT AND ENTRY
These studies thus showed that HS binding to CXCR4 tropic gp120
is constitutive (the V3 loop -which dominates the interaction- is
surface exposed), and can be enhanced by CD4 (which, together
with V3 loop reorganization, exposes a new HS binding domain),
while it is entirely CD4-induced for CCR5 tropic gp120. Inter-
estingly, all these HBDs are located close to each other, at the
proximity of- or within- the co-receptor binding site and are col-
lectively involved in the conformational changes induced upon
interaction with CD4 and in co-receptor recognition. In partic-
ular, mutations of Arg-419, Lys-421, Lys-432 within the bridging
sheet, and Arg298, Arg306, Arg308, within the V3 loop, which
are targeted by heparin, decrease the ability of gp120 to inter-
act with CXCR4. This strongly suggested that polyanionic com-
pounds, in addition to prevent HIV-1 association to cell surface
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FIGURE 4 |TheV3 loop and the co-receptor binding domain of gp120
features HS binding sites. (A)The gp120 CD4-induced domain displays a
HS binding structure. The Connolly surface of the HXBc2 gp120 core was
color-coded according to the electrostatic potential from negative values
(blue) to positive values (red). The basic residues of the CD4-induced (CD4i)
epitope, which form a HS binding site, are indicated. (B) Representation of
the lowest energy model of a gp120/HS derived octasaccharide complex.
The protein [orientation as in (A)] is represented by a ribbon, and the
octasaccharide by sticks. (C) Lowest energy model of the gp120 (on which
the Connolly surface was calculated) in complex with a HS derived
octasaccharide. V1/V2 and V3 indicate the stem of the V1/V2 and V3 loops.
The location of the CD4i epitope is also indicated. (D) Structure of gp120, on
which the V3 loop (in blue) was modeled. The HS binding residues of the V3
loop and the CD4-induced epitope are aligned on the surface of the protein
and form an extended binding site on which has been docked a HS derived
oligosaccharide of appropriate length. (E) Connolly surface of gp120,
including the V3 loop, in complex with a tetradecasaccharide shown with
the same orientation as in (C).
HSPG, could directly block co-receptor binding and thus inhibit
entry. However, being cryptic on the HIV-1 associated gp120, the
co-receptor binding site needs to be exposed to be efficiently tar-
geted. To this aim, a new molecule composed of CD4 covalently
linked to HS has been prepared. To render this molecule poten-
tially druggable it was based on a small CD4 mimetic (rather
than recombinant CD4) and a chemically synthesized HS dode-
camer (rather than natural derived HS, whose almost infinite
structural variety would have made impossible the obtention of
a defined compound). This chemically defined glycoconjugate
(termed mCD4-HS12), whose size is 6000 Da, was shown to bind
to gp120 through its mCD4 moiety and induce the structural
modifications necessary to expose the co-receptor binding domain
which therefore became available to be blocked by the HS12
moiety (Figure 5). This compound thus successfully targets two
critical and highly conserved domains of gp120; the CD4 and
the co-receptor binding domains. From a biochemical point of
view, this compound blocks the binding of the prototypic R5-
gp120 (YU2), to both CD4 and mAb 17b (directed against the
co-receptor binding domain), while it blocks that of the pro-
totypic X4-gp120 (MN) to CD4, HS and mAb 17b, with low
nanomolar affinity (99). This molecule also prevents gp120 associ-
ation to purified native CCR5 and CXCR4 co-receptors (100) and
consequently displays a strong antiviral activity against R5- and
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FIGURE 5 | Principe of inhibition of HIV-1 attachment and entry by
“CD4-HS.” (A) A CD4 mimetic peptide covalently linked to a HS
dodecassaccharide (CD4-HS) bind to gp120 through its CD4 moiety and
exposes the CD4i epitope, which then becomes available for interaction with
the oligosaccharide. Such a bivalent molecule simultaneously binds to the
CD4, the HS and the co-receptor binding sites of gp120 and blocks the
interaction of the virus with all its principal cell surface ligands, inhibiting both
attachment and entry (The gp120 was schematically represented as in
Figure 3). (B)The structure of the mCD4-HS12 is also shown [modified from
Ref. (99)].
X4- HIV-1 as well as against dual tropic virus with IC50 as low
as 5 nM.
CONCLUSION AND PERSPECTIVE
Investigation of the gp120 binding to HS has revealed a contrasting
situation that is far more complex than previously thought. HIV-
1 that uses CXCR4 as an entry co-receptor features up to four
HBDs on their gp120, including the V1/V2 and V3 loops and the
co-receptor binding site, while those using CCR5 mostly display
HS binding activity essentially within the conserved and charac-
teristically basic co-receptor binding domain. In that context, it is
worth noting that the N-terminus of CCR5 and CXCR4 contain
sulfotyrosine, as do a number of antibodies, directed against the
gp120 co-receptor binding domains (101), also indicating that the
gp120 CD4 induced region can be liganded by sulfated moieties.
Characterization of these HBDs, in particular within the CD4
induced surface, whose cryptic nature limits its accessibility both
temporally and spatially during infection, led to the engineering
of a new class of compounds in which HS was covalently linked to
mCD4. These compounds, conceptually distinct from any other
existing HIV-1 inhibitors, function by simultaneously exposing
and blocking the HIV-1 co-receptor binding site, and therefore
inhibit binding of gp120 to both CD4 and CCR5/CXCR4. It thus
efficiently inhibits viral replication by blocking entry, which is
currently considered as a compelling target for controlling viral
replication (102). This molecule also inhibits the binding of gp120
to HS and has thus the potential for preventing viral adsorption
on mucosa or viral transport through the blood brain barrier. It
could therefore be further developed for both prevention and ther-
apy following topical and/or parenteral application. In this regard,
it is worth noting that these compounds are much more defined
and have a much more specific mode of action than the above
described polyanions that have been investigated up to now.
Despite tremendous progresses made in the development of
antiviral drugs (103), HIV-1 continues to be a major health con-
cern and remains one of the leading causes of death worldwide,
which necessitate the development of new antivirals. With regards
to inhibitor development, it is worth noting that mCD4-HS12
is bivalent. Multivalency has a number of functional advantages,
such as achieving high affinity, and increasing strength and speci-
ficity for the binding site. It has been indeed found that the
mCD4-HS12 is, by far, more active than either its moieties alone,
each reciprocally enhancing the blocking activity of the other in a
cooperative manner (99). Targeting the gp120 co-receptor binding
site, which although is well conserved across various HIV-1 strains
exists in a dynamic equilibrium between its unliganded- and CD4-
bound conformations, might thus be relatively challenging. From
a structural point of view, it is interesting that HS is character-
ized by considerable internal motion and variation in its local
three-dimensional structure. The IdoA, in particular, also exists in
a dynamic equilibrium between a chair and a twisted skew-boat
form, which may itself represent the average of a rapidly fluc-
tuating ensemble of related structures. The conformation of HS
also depends on its local sequence, the presence of poorly sulfated
GlcA-GlcNAc domains giving rise to chain flexibility (104). It is
thus tempting to suggest that HS is well designed to interact with
an ensemble of conformationally dynamic structures such as that
of the co-receptor binding domain of gp120, the high specificity
of the conjugated bivalent compound being brought by the mCD4
moiety.
Currently, the HS12 moiety of the molecule displays a regular
and highly sulfated sequence, (2-O-sulfated iduronic acid linked
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to N - and 6-O-sulfated glucosamine), so that the exact sulfation
pattern recognized by gp120 is hidden in the fully sulfated oligosac-
charide. HS synthesis is notoriously difficult, and in view of its
huge diversity (see Figure 1), the synthesis of a library addressing
structure-activity relationships is not realistic. In an effort to pin-
point the sulfate groups that are functionally essential to gp120
binding, the HS was substituted with sulfotyrosine-containing HS
mimetic peptide, the synthesis of which is much more straightfor-
ward, and more easily amenable to sequence-activity relationship
investigation. This molecule compares very well with HS12, and
when conjugated to mCD4 broadly inhibits the replication of sev-
eral HIV-1 strains with an IC50 of 1 nM (100), thus, opening the
route to future developments.
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